Request a Quote
Skip to main content

Quinolone resistance in poultry: gyrA S83L and qnrS1 data

Quinolone resistance in poultry is not a laboratory abstraction. A survey of 200 retail egg packs found that 80.0% of eggshell Escherichia coli isolates were non-wild-type to at least one quinolone. gyrA S83L and the plasmid gene qnrS1 dominated the sequenced subset. Sulfamethoxazole resistance reached 34.0%.

For anyone formulating or prescribing water-soluble antimicrobials in layers and broilers, the useful question is narrower than the headline number: which mechanisms are actually on the eggshell surface, and what do they take off the treatment menu? Nine months of phenotype and whole-genome data give a workable answer.

Why eggshell E. coli is a useful resistance sentinel

Contamination of the shell happens after lay. Feces, litter, dust, cages, belts and handling equipment all contribute. The hen's intestinal, urinary and reproductive tracts share a cloacal opening, so intestinal bacteria such as E. coli reach the shell easily. A shell is therefore a passive sampler for whatever Gram-negative population is moving through a flock.

Two design choices raise this dataset above a generic contamination count. Eggshells and egg contents were processed as separate pooled matrices, which separates external from internal contamination. Susceptibility was also read against epidemiological cut-offs instead of clinical breakpoints, so wild-type populations stay distinguishable from isolates that have merely drifted upward in MIC.

The second point pays off. E. coli was recovered from 50 of 200 eggshell pools at 25.0% (95% CI 19.2 to 31.6). None of the 200 egg-content pools yielded the organism under the analytical conditions used (0.0%, 95% CI 0.0 to 1.8). This was an outside-surface phenomenon.

Study design and analytical conditions

Parameter

Detail

Sampling window

October 2024 to June 2025

Sampling unit

Sealed retail pack of 12 table eggs

Packs tested

200 packs, 2400 individual eggs

Matrices

Eggshell pool and egg-content pool processed separately per pack

Brand origin

Local domestic brands and imported packs from three countries

Susceptibility panel

EUVSEC3 microdilution panel

Breakpoint convention

EUCAST epidemiological cut-offs (ECOFF)

Isolates tested phenotypically

50, one per positive eggshell pool

Isolates sequenced

20 selected, 19 retained after quality control

Sequencing readout

Resistance genes, resistance mutations, MLST, phylogroup, virulence genes

Detection association test

Two-sided Fisher exact test at pack level, unadjusted

Sample size followed an assumed E. coli prevalence of 25%, taken from the upper confidence limit of a recent global meta-analysis that pooled table-egg E. coli prevalence at 18.5% (95% CI 12.6 to 25.0). The calculation used 90% confidence and 5% precision.

The phenotype data: quinolones lead, folate inhibitors follow

Forty-four of the 50 isolates (88.0%) were non-wild-type to at least one antimicrobial class. Six (12.0%) stayed wild type across the whole panel. The distribution is uneven across drug families.

Antimicrobial

Non-wild-type isolates

Percent of 50

Ciprofloxacin

38

76.0

Nalidixic acid

30

60.0

Tetracycline

24

48.0

Ampicillin

23

46.0

Chloramphenicol

20

40.0

Sulfamethoxazole

17

34.0

Trimethoprim

13

26.0

Colistin

0

0.0

Meropenem

0

0.0

Tigecycline

0

0.0

Class level repeats the same ordering: quinolones 40 of 50 (80.0%), beta-lactams 25 (50.0%), tetracyclines 24 (48.0%), folate pathway inhibitors 21 (42.0%), phenicols 20 (40.0%), aminoglycosides 6 (12.0%), macrolides 1 (2.0%).

Two readings deserve separation. Nalidixic acid, the older narrow-spectrum member of the group, sat at 60.0%, below ciprofloxacin rather than above it. That pattern fits accumulated gyrA-type change rather than one discrete mechanism. The folate pathway pair also behaves as a pair: sulfamethoxazole at 34.0% and trimethoprim at 26.0% combine into a class figure of 42.0%, because 21 isolates were non-wild-type to at least one of the two.

Multiclass resistance, meaning non-wild-type to three or more classes, appeared in 26 of 50 isolates (52.0%, 95% CI 37.4 to 66.3). The spread was eight isolates (16.0%) at three classes, five (10.0%) at four, 11 (22.0%) at five, and two (4.0%) at six.

Detection frequency by production system and brand origin

Recovery tracked the production system printed on the pack label. Cage-laid packs returned 48 positives from 170 (28.2%, 95% CI 21.6 to 35.6). Cage-free packs returned two from 30 (6.7%, 95% CI 0.8 to 22.1). The two-sided Fisher exact test gave P = 0.011 at pack level, unadjusted.

Stratum

Tested

Positive

Percent

95% CI

Eggshell pool, all packs

200

50

25.0

19.2 to 31.6

Egg content, all packs

200

0

0.0

0.0 to 1.8

Cage-laid packs

170

48

28.2

21.6 to 35.6

Cage-free packs

30

2

6.7

0.8 to 22.1

Of the 50 positive shell pools, 41 came from local brands and nine from imported packs: four from Oman, three from Turkey, two from India. The cage-laid versus cage-free difference is an unadjusted association. The cage-free interval is wide enough that it should not be read as a husbandry verdict.

The genome: gyrA S83L and qnrS1 in the same population

Nineteen isolates passed quality control. One was dropped because its assembly was 10.72 Mbp against an expected 4.10 to 6.30 Mbp, with 1,246 contigs against a limit of 700. The 19 retained genomes carried 32 resistance markers between them, each in at least one isolate.

Determinant

Class

Isolates

Percent of 19

gyrA S83L

Quinolone, chromosomal

12

63.2

qnrS1

Quinolone, plasmid-mediated

8

42.1

gyrA D87N

Quinolone, chromosomal

3

15.8

parC S80I

Quinolone, chromosomal

3

15.8

parE S458A

Quinolone, chromosomal

2

10.5

tet(A)

Tetracycline

14

73.7

blaTEM-1

Beta-lactam

10

52.6

blaCTX-M-55

Beta-lactam, extended spectrum

1

5.3

cmlA1

Phenicol

8

42.1

floR

Phenicol

4

21.1

mph(A)

Macrolide

3

15.8

lnu(F)

Lincosamide

1

5.3

fosA4

Fosfomycin

1

5.3

uhpT E350Q

Fosfomycin

2

10.5

qacL

Quaternary ammonium antiseptic

9

47.4

Quinolone determinants were the commonest class-level finding, present in 16 of 19 sequenced isolates (84.2%). Two mechanism families sit side by side. A chromosomal target modification, gyrA S83L, appeared in 12 isolates. A plasmid-carried protection protein, qnrS1, appeared in eight. Three isolates carried gyrA D87N and three carried parC S80I, the second-step changes that push MICs further up the class.

A formulator should read this paragraph twice. Norfloxacin and the rest of the quinolone group kill by trapping DNA gyrase and topoisomerase IV. A S83L substitution in the gyrase A subunit lowers binding affinity for the whole class, not for one molecule. The same substitution degrades nalidixic acid, ciprofloxacin and norfloxacin together. A qnrS1 plasmid adds a second, transferable layer on top. Where a flock population carries both, raising the dose does not restore activity, because the change sits in the target rather than in exposure.

Population structure argues against one expanding clone. Multilocus sequence typing resolved 12 sequence types, with ST202 commonest at six isolates (31.6%). The dominant combined CH profile was fumC11 at six isolates (31.6%), then fumC65-fimH32 at three (15.8%). Isolates spread across four phylogroups, led by B1 with nine and A with eight. A single-nucleotide polymorphism phylogeny split the isolates into multiple branches with no defined cluster.

Virulence gene carriage ran from zero genes in one isolate to 24 in another. The commonest adhesion gene was fdeC in 11 isolates (57.9%), then lpfA-O113 in nine (47.4%) and iha in eight (42.1%). High resistance and high virulence did not travel together.

The counterintuitive finding: a clean colistin result next to a dirty quinolone result

A food-chain survey reporting 52.0% multiclass resistance would be expected to flag the last-resort agents too. This one does not. Every isolate stayed wild type for colistin, meropenem and tigecycline, and no plasmid-mediated colistin determinant appears in the sequenced subset.

That combination informs more than it reassures. Colistin and meropenem see no use in layer production at any scale, so the shell population carries no selective pressure toward those mechanisms. Quinolones and folate pathway inhibitors do see use, and they sit at 80.0% and 42.0% at class level. Resistance tracks exposure, and the exposure profile of a layer operation is narrow: mostly water-administered and feed-administered agents aimed at enteric and systemic Gram-negative infection.

The extended-spectrum beta-lactamase signal is the second surprise, and it is nearly absent. blaTEM-1 appeared in 10 isolates. blaCTX-M-55 appeared in exactly one. Reporting only class-level beta-lactam resistance at 50.0% would overstate the ESBL problem here by an order of magnitude. Reading quinolone resistance in poultry the same way, as a class figure of 80.0%, is the safer habit.

How quinolone resistance in poultry changes a treatment protocol

  • A non-wild-type quinolone result is a class verdict, not a molecule verdict. gyrA S83L in 63.2% of sequenced isolates means a switch from one quinolone to another inside the class buys nothing.
  • Test for qnrS1 when a farm reports repeated quinolone failures with susceptible-looking MICs. Plasmid-mediated protection produces low-level shifts that are easy to miss, not clean resistance.
  • Read sulfamethoxazole and trimethoprim together. The folate pathway class figure of 42.0% exceeds either single agent, and a combination product depends on both components being active.
  • Do not treat a cage-free label as removal of resistance risk. The cage-free stratum gave two positives from 30, a point estimate on a wide interval.
  • Decide whether the isolate is a hygiene indicator or a pathogen before changing a protocol. This population was genomically heterogeneous, with 12 sequence types and virulence carriage from zero to 24 genes.

Limitations

The survey covers retail packs from three cities in one country across nine months, so the prevalence estimates belong to that market and period. The cage-laid versus cage-free comparison is unadjusted and rests on 30 cage-free packs. Phenotyping used a fixed panel, so agents outside it went untested. Whole-genome sequencing covered 19 of 50 isolates, selected rather than random, and gene counts for markers found in fewer than three isolates carry wide uncertainty. Egg content was negative under the enrichment and plating conditions used, which does not prove absence at lower concentrations. No flock-level treatment records were linked to the packs, so the exposure argument, including the claim that quinolone resistance in poultry tracks drug-class usage, is inference from usage patterns rather than measured drug use.

Bottom line

Quinolone resistance in poultry eggshell E. coli is a target-site problem first and a plasmid problem second. The 76.0% ciprofloxacin and 60.0% nalidixic acid non-wild-type rates, with gyrA S83L in 63.2% and qnrS1 in 42.1% of sequenced isolates, describe a population where the class is compromised before any single product is chosen. Norfloxacin programs in layers and broilers need flock-level susceptibility data, not label-based assumptions. The 34.0% sulfamethoxazole figure says the same about the folate pathway pair, and the fully wild-type colistin result shows the profile is shaped by what the operation uses.

FAQ

What does quinolone resistance in poultry actually look like on a lab report?

It usually appears as a modest MIC increase rather than a dramatic one. In this survey, 76.0% of eggshell E. coli isolates were non-wild-type to ciprofloxacin and 60.0% to nalidixic acid when read against epidemiological cut-offs, while 12.0% of isolates stayed wild type across the entire panel. A report that uses clinical breakpoints instead of cut-offs will show fewer flagged isolates and hide the drift.

Which genes drive quinolone resistance in these isolates?

Two families dominate. Chromosomal target mutations, led by gyrA S83L in 12 of 19 sequenced isolates (63.2%), with gyrA D87N and parC S80I in three isolates each. And plasmid-mediated protection, with qnrS1 in eight isolates (42.1%). A further two isolates carried parE S458A. Sixteen of the 19 sequenced isolates carried at least one quinolone determinant.

Does switching to a different quinolone solve a gyrA problem?

No. The gyrA S83L substitution changes the drug binding site on DNA gyrase, and every quinolone relies on that same site. A population carrying this mutation shows reduced susceptibility across the class, which is why the survey reports class-level quinolone non-wild-type at 80.0% while individual agents range from 60.0% to 76.0%. Changing molecule within the class does not restore activity.

Why was sulfamethoxazole included in a quinolone story?

Because the two product families sit in the same treatment decisions for enteric Gram-negative infection in poultry. Sulfamethoxazole showed 34.0% non-wild-type and trimethoprim 26.0%, combining to a folate pathway class figure of 42.0% across 21 isolates. A formulator choosing between a quinolone and a sulfonamide-potentiated program needs both numbers, not one.

How common is multiclass resistance in this dataset?

Twenty-six of 50 isolates (52.0%, 95% CI 37.4 to 66.3) were non-wild-type to three or more antimicrobial classes. The breakdown was eight isolates at three classes, five at four, 11 at five, and two at six. Six isolates (12.0%) were wild type across the entire panel, so the population is genuinely mixed rather than uniformly resistant.

Is colistin resistance a concern in these eggs?

Not in this sample. All 50 isolates retained wild-type phenotypes for colistin, meropenem, and tigecycline, and no plasmid-mediated colistin determinant appeared among the 19 sequenced genomes. The authors frame this as absence of selective pressure, since these agents are not used in layer production, rather than as evidence of good stewardship.

Does the production system change the resistance picture?

Recovery differed, resistance did not follow cleanly. Cage-laid packs yielded E. coli in 48 of 170 (28.2%) and cage-free packs in two of 30 (6.7%), a difference that was significant at pack level before adjustment (P = 0.011). The cage-free stratum is small and its confidence interval runs from 0.8% to 22.1%, so it cannot support a claim that cage-free eggs carry less resistant flora.

What is the difference between a non-wild-type phenotype and clinical resistance?

A non-wild-type phenotype means the MIC sits above the epidemiological cut-off for the wild-type population, which signals acquired reduced susceptibility. Clinical resistance means the MIC exceeds a treatment-relevant breakpoint for that drug, dose, and species. The first is a surveillance signal available before treatment failure; the second requires clinical breakpoints that do not exist for every veterinary agent.

Which sequencing markers matter most for a veterinary diagnostic lab?

Three carry the most decision value: gyrA at codon 83 for the quinolone class, qnrS1 for transferable low-level quinolone resistance, and the folate pathway markers behind sulfamethoxazole and trimethoprim non-wild-type phenotypes. In this dataset, 32 resistance markers appeared across 19 genomes, so a narrow panel that covers these three families captures the clinically actionable share.

How should a formulator use a 34.0% sulfamethoxazole figure?

As a reason to demand isolate-level susceptibility before committing a flock to a potentiated sulfonamide program. The figure describes a retail eggshell population, not a sick flock, but it sets the prior probability that a random enteric isolate will already be non-wild-type. Where the prior is that high, culture and susceptibility testing before treatment is cheaper than a failed course.

Do these isolates come from one spreading clone?

No. The sequenced subset resolved into 12 sequence types, with ST202 the most frequent at six isolates (31.6%), and spread across four phylogroups led by B1 and A. The single-nucleotide polymorphism phylogeny showed multiple branches and no defined cluster. That pattern fits repeated independent selection in many flocks rather than one clone moving through a supply chain.